Recombinant Fc-conjugated PD-L1 is a promising biologic for achieving anti-inflammatory effects with IBD therapy due to the suppression of immune cells and their cytokine production via interactions with PD-1 and B7-117. This evidence concerns the gene CD274 and inflammatory bowel disease.